Here, the effect of dasatinib on treatment of Bcr/Abl-positive acute lymphoblastic leukemia (ALL) cells was evaluated in the presence of stromal support. Dasatinib eradicated Bcr/Abl ALL cells ...

Pediatric patients with ALL were found to experience deficits in their motor skills between at least 1 month and 4 years after completing treatment.